ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,691.37
-1.80%
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs Yen
158.4565
0.20%
Brent Oil
83.075
-1.50%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) ニュース

CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CTMX
日付受信時刻ニュースソース見出しコード企業名
2024/02/2722 : 00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
2024/01/2422 : 00GlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2bNASDAQ:CTMXCytomX Therapeutics Inc
2024/01/2010 : 44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2024/01/2010 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2024/01/2010 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2024/01/2010 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2024/01/2010 : 37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2024/01/1222 : 00GlobeNewswire Inc.CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
2024/01/0422 : 00GlobeNewswire Inc.CytomX Therapeutics Outlines 2024 Company Priorities and MilestonesNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2306 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2306 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2306 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2306 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2122 : 00GlobeNewswire Inc.CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2009 : 58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2009 : 57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2009 : 56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/12/2009 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/11/0806 : 15GlobeNewswire Inc.CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
2023/11/0806 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
2023/11/0806 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTMXCytomX Therapeutics Inc
2023/11/0121 : 00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
2023/10/3121 : 00GlobeNewswire Inc.CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:CTMXCytomX Therapeutics Inc
2023/10/3021 : 00GlobeNewswire Inc.CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual MeetingNASDAQ:CTMXCytomX Therapeutics Inc
2023/10/1905 : 30GlobeNewswire Inc.CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
2023/09/2308 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/09/2308 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/09/2308 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
2023/09/0605 : 05GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
2023/08/2813 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CTMXCytomX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CTMX

最近閲覧した銘柄

CCOM
US30
US 30
CCOM
US100
US Tech 100
NYSE
MRK
Merck
CCOM
US500
US 500
NYSE
VZ
Verizon Communications
NYSE
MCD
McDonalds
USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
NYSE
CVX
Chevron
PM
XAUUSD
Gold vs US Dollar
AMEX
SPY
SPDR S&P 500
COIN
ETHUSD
Ethereum
USOTC
ADDYY
Adidas (QX)
NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有